Kristie L. Kahl
Articles
Adagrasib Associated With Promising Disease Control Rate in KRAS G12C–Mutant NSCLC
June 09, 2022
Article
Investigators reported an objective response rate of 43% and a disease control rate of 80% among patients with previously treated KRAS G12C–mutated non–small cell lung cancer who received the KRAS G12C inhibitor adagrasib.
Survival Benefit Observed With Nimotuzumab Plus Chemo in KRAS Wild-Type Advanced Pancreatic Cancer
June 04, 2022
Article
Patients with KRAS wild-type pancreatic cancer elicited a significant survival benefit with the addition of nimotuzumab to gemcitabine vs placebo plus gemcitabine in a phase 3 trial.
R-Mini-Chop Plus Ibrutinib Extends Progression-Free Survival in Elderly Patients With Newly Diagnosed DLBCL
December 13, 2021
Article
Combining ibrutinib with rituximab resulted in improved 2-year progression-free survival among elderly patients with previously untreated diffuse large B-cell lymphoma.
Bone-Protecting Agents Reduce Fracture Risk During Prostate Cancer Treatment
June 09, 2021
Article
Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who are being treated with radium-223 (Xofigo) plus enzalutamide (Xtandi) can reduce their risk of fractures with the use of bone-protecting agents.
Second-Generation CAR T-Cell Therapy Is ‘Highly Promising’ in Relapsed/Refractory B-NHL
June 08, 2021
Article
The second-generation 4-1BB bi-specific CAR T-cell therapy was efficacious and safe in treating patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Tivozanib Tolerability Shows Potential Advantage for Patients with Advanced RCC
May 20, 2020
Video
Oncology Nursing News sat down with Brian Rini, MD, from the Vanderbilt-Ingram Cancer Center (VICC), to discuss results from the phase III TIVO03 trial, and its potential impact on patients with relapsed or refractory renal cell carcinoma.
Integrated Geriatric Assessment Optimizes Care for Older Adults with Cancer
May 14, 2020
Article
By integrating a comprehensive geriatric assessment with geriatrician-led management care researchers found an improved quality of life for older adults with cancer.
FDA Approves Encorafenib Plus Cetuximab for Metastatic CRC with BRAF V600E Mutation
April 09, 2020
Article
The FDA approved the combination use of encorafenib and cetuximab for the treatment of adult patients with BRAFV600E-positive metastatic colorectal cancer.
FDA Approves Pemetrexed for Injection for Nonsquamous Non-Small Cell Lung Cancer
February 10, 2020
Article
The agency granted full approval to pemetrexed for injection (Pemfexy), a liquid injection and branded alternative to Alimta, for nonsquamous NSCLC.